Company: OSRH
Filing Date: 2025-01-31
Form Type: 424B3
Source: 0001213900-25-008874
Chunk: 407

Company: OSR Holdings, Inc.
Filing Date: 2025-01-31
Form: 424B3
Chunk 407
---
 (8.0)                 |     | 3 (12.0)              |
| SD                    |     | —                      |     | 3 (12.0)                |     | 1 (4.0)               |
| PD                    |     | 2 (66.7)               |     | 20 (80.0)               |     | 21 (84.0)             |
| ORR (%) [95% CI]      |     | 33.3 [0.8 – 90.6]      |     | 8.0 [1.0 – 26.0]        |     | 12.0 [2.5 – 31.2]     |
| DCRR (%) [95% CI]     |     | 33.3 [0.8 – 90.6]      |     | 20.0 [6.8 – 40.7]       |     | 16.0 [4.5 – 36.1]     |

Note: A hyphen (-) indicates no events were reported. n = number of patients with an event; N = number of patients; NR = non -resectable . Percentages are based on the number of patients. CR = complete response; P R = partial re mission; SD = stable disease; PD = progressive disease; ORR = objective response rate (CR and PR); DCR = disease control rate (CR, PR, and SD). The clinical response was assessed by recurrence -freesurvival after re -operation(RFS) (in the 10 7CFU/mL resectable group), time -to -progression(TTP), progression free survival (PFS), and overall survival (OS). In the patients who underwent tumor resection (10 7CFU/mL resectable group), disease progression occurred only in Patient 01 -17with an RFS of 1.8. Patient 01 -14was censored with an RFS of 20.9 months. The results for TTP and PFS were identical, with an overall median of 2.7 months and range of 1.2 to 13.8 months in the non -resectedpatients (Total NR group). The median OS in the Total NR group was 11.1 months (95% CI: 8.5 – 15.1) with a range of 3.8 to 38.